Imara Receives Rare Pediatric Disease Designation from FDA for Lead Product Candidate IMR-687 for Sickle Cell Disease

Imara, Inc., a biotechnology company and Connect4Strategies client dedicated to developing novel therapeutics for patients with sickle cell disease (SCD) and other hemoglobinopathies, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to IMR-687, the company’s lead product candidate. IMR-687 is the first SCD candidate to be designated as a drug for a rare pediatric disease, and this designation builds upon, and is complimentary to, the FDA’s earlier grant of Orphan designation.